The prognosis of FLT3-ITD mutations is determined by the allelic ratio and co-mutation with NPM1. In the European LeukemiaNet stratification of AML, FLT3-ITD mutations with allelic ratios of FLT3-ITD to FLT3-WT less than 0.5 with a concomitant NPM1 are favorable, FLT3-ITD mutations with allelic ratios of FLT3-ITD to FLT3-WT <0.5 without a concomitant NPM1 or FLT3-ITD with high (FLT3-ITDhigh) allelic ratios (>0.5) with a concomitant NPM1 mutation are intermediate risk, and FLT3-ITDhigh with wild type NPM1 is considered adverse risk [12]. The gene discussed is FLT3; the disease is acute myeloid leukemia.